2024 ESMO Asia | 先睹为快！结直肠癌领域哪些中国研究入选？

前言

mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody in Locally Advanced MSS CRC (BASKETⅡ): A Prospective, Single-Arm, Open-Label, Phase II Study

mFOLFOX6+贝伐珠单抗+PD-1抗体治疗局部晚期MSS CRC(BASKETⅡ)：一项前瞻性、单臂、开放标签、II期研究

讲者：黄俊 中山大学附属第六医院

Anlotinib plus Sintilimab as First-line Treatment for Patients with Advanced Colorectal Cancer (APICAL-CRC): an Open-Label, Single-arm, Phase II study

安罗替尼联合信迪利单抗作为晚期结直肠癌患者的一线治疗 (APICAL-CRC)：一项开放标签、单组、 II 期研究

讲者：王湛 上海长征医院

Efficacy and safety of iparomlimab and tuvonralimab (QL1706) in untreated metastatic colorectal cancer (mCRC)

iparomlimab 和 tuvonralimab (QL1706) 对未经治疗的转移性结直肠癌 (mCRC) 的疗效和安全性

讲者：李进 中国药科大学附属上海高博肿瘤医院

Design and Optimization of Colorectal Cancer Neoantigens mRNA Vaccines with a naturel TLR-Stimulating Adjuvant

天然TLR刺激辅助结直肠癌新抗原mRNA疫苗的设计与优化

讲者：Saber Imani 浙江树人学院

Split-Course Hypofraction Radiotherapy Combined with Chemotherapy and Tislelizumab as Preoperative treatment for Locally Advanced Rectal Cancer: Interim Analysis of A Prospective, Single-Arm Phase II Trial

分段低分割放疗联合化疗和替雷利珠单抗作为局部晚期直肠癌术前治疗：前瞻性单组 II 期临床试验的中期分析

讲者：Benhua Xu 福建医科大学附属协和医院

Stereotactic body radiation therapy followed by fruquintinib in combination with immunotherapy as third- and later-line treatment in metastatic colorectal cancer

立体定向放射治疗联合呋喹替尼与免疫疗法作为转移性结直肠癌的三线及后续治疗

讲者：Yi Wang 宁波市第二医院

Results from FRONT study: A multicenter, randomized, open-label clinical trial of fruquintinib as maintenance therapy after 1L treatment in metastatic colorectal cancer (mCRC)

FRONT 研究结果：一项关于呋喹替尼作为转移性结直肠癌 (mCRC) 一线治疗后维持治疗的多中心、随机、开放性临床试验

讲者：Xiaojing Xu 复旦大学附属中山医院

Efficacy and safety of cetuximab plus raltitrexed as first-line maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC) : an interim analysis of a multi-center phase II trial

西妥昔单抗联合雷替曲塞作为 RAS 野生型转移性结直肠癌 (mCRC) 患者一线维持治疗的疗效和安全性：一项多中心 II 期试验的中期分析

讲者：Sheng Li 南京医科大学附属肿瘤医院

ZNF334 Contributes to 5-Fluorouracil Sensitivity in Colorectal Cancer by Ubiquitination Modification of CDK1-cylin B1

ZNF334 通过泛素化修饰 CDK1-细胞周期蛋白 B1 提高结直肠癌对 5-氟尿嘧啶的敏感性

讲者：Ran Sun 重庆市九龙坡区人民医院

ADAR1 of T cells rather than epitheliums contributes the bulk expression and induces immune exhaustion in colorectal cancer

T 细胞而非上皮细胞的ADAR1基因大量表达并诱导结直肠癌的免疫衰竭

讲者：张荣欣 中山大学肿瘤防治中心

Liposomal irinotecan + 5-FU/LV + bevacizumab for second-line treatment of metastatic colorectal cancer (IRIS): a prospective, multi-center, single-arm clinical study

脂质体伊立替康 + 5-FU/LV + 贝伐珠单抗用于转移性结直肠癌 (IRIS) 的二线治疗：一项前瞻性、多中心、单组临床研究

讲者：Xuhua Hu 河北医科大学第四医院

Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer

高强度聚焦超声（HIFU）治疗结直肠癌肝转移的临床观察及免疫影响

讲者：Shasha Wang 青岛大学附属医院

A Study on the Effect of Prognostic Nutritional Index on the Safety and Survival of Patients With Metastatic Colorectal Cancer Receiving Three Lines of Regorafenib and Above

预后营养指数对接受三线及以上瑞戈非尼治疗的转移性结直肠癌患者安全性和生存期影响的研究

讲者：Zeng Wang 浙江省肿瘤医院

Anlotinib plus chemotherapy as first-line (1L) treatment in gastrointestinal cancer patients with unresectable liver metastases

安罗替尼联合化疗作为不可切除肝转移的胃肠道癌症患者的一线 (1L) 治疗

讲者：吴珺玮 上海交通大学医学院附属瑞金医院

Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients with Colon and Upper Rectal Cancer: A multicenter, prosopective, randomized phase III study

结肠和直肠上段癌患者接受缩孔腹腔镜手术的安全性和有效性：一项多中心、前瞻性、随机 III 期研究

讲者：Zhimin Liu 中山大学附属第六医院

Neoadjuvant CAPOX plus SCT510 (bevacizumab biosimilar) and finotonlimab in high-risk resectable colorectal liver metastases (CRLM): a multicenter, phase II study

新辅助 CAPOX 联合 SCT510（贝伐珠单抗生物仿制药）和 finotonlimab 治疗高风险可切除结直肠肝转移 (CRLM)：一项多中心 II 期研究

讲者：邱文生 青岛大学附属医院

A randomized, controlled, multicenter phase 3 study of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) as neoadjuvant treatment for resectable microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colon cancer: Trial in Progress

一项随机、对照、多中心 3 期研究，探讨 IBI310（抗 CTLA-4 抗体）联合信迪利单抗（抗 PD-1 抗体）作为可切除微卫星不稳定性高/错配修复缺陷 (MSI-H/dMMR) 结肠癌的新辅助治疗：正在进行中的试验

讲者：徐瑞华 中山大学肿瘤防治中心

Neoadjuvant short-course radiotherapy combined with chemotherapy and cadonilimab for patients with locally advanced rectal cancer: A prospective, single-arm phase II trial

新辅助短程放疗联合化疗和卡度尼利单抗治疗局部晚期直肠癌：一项前瞻性、单臂 II 期试验

讲者：Jiawei Rao 中山大学附属第一医院

Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Lower Rectal Cancer: A multicenter, prospective, randomized control study

低位直肠癌 Parks 和 Bacon 吻合术后的肛门功能比较：一项多中心、前瞻性、随机对照研究

讲者：Zhimin Liu 中山大学附属第六医院

Watch and wait in patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after PD-1 monoclonal antibody therapy (BASKET)

DNA错配修复缺陷或微卫星高度不稳定的远端直肠癌患者接受PD-1单克隆抗体治疗后实现病理完全缓解并接受观察等待（BASKET）

讲者：Fang He 中山大学附属第六医院

Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer

动态多组学整合模型预测局部晚期直肠癌的新辅助治疗反应

讲者：Yandong Zhao 中山大学附属第六医院

Safety and efficacy of PD-1 monoclonal antibody with or without mFOLFOX6 neoadjuvant therapy in patients with local advanced deficient mismatch repair/microsatellite instability-high synchronous multiple primary colorectal cancer

局部晚期错配修复缺陷/微卫星高度不稳定同时多原发性结直肠癌患者接受PD-1单抗联合或不联合 mFOLFOX6 新辅助治疗的安全性和有效性

讲者：Yandong Zhao 中山大学附属第六医院

Prophylactic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Locally Advanced Colonrectal Cancer: A Single-centre, open-label, randomized controlled trial

局部晚期结肠直肠癌的预防性腹腔热灌注化疗 (HIPEC)：一项单中心、开放标签、随机对照试验

讲者：Shiyu Xu 中山大学附属第一医院